Abstract
The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Current Drug Discovery Technologies
Title: High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions
Volume: 5 Issue: 3
Author(s): Pierre Colas
Affiliation:
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Abstract: The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Export Options
About this article
Cite this article as:
Colas Pierre, High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions, Current Drug Discovery Technologies 2008; 5 (3) . https://dx.doi.org/10.2174/157016308785739875
DOI https://dx.doi.org/10.2174/157016308785739875 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Occupational Risk Assessment of Engineered Nanomaterials: Limits, Challenges and Opportunities
Current Nanoscience An Overview of Highly Optically Pure Chloramphenicol Bases: Applications and Modifications
Mini-Reviews in Medicinal Chemistry Safety and Quality of Nutraceuticals: Have FSSAI Guidelines been Able to Blaze the Trail?
Applied Clinical Research, Clinical Trials and Regulatory Affairs Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products
Current Drug Targets C-glycosyl Flavone from Urginea indica Inhibits Growth and Dissemination of Ehrlich Ascites Carcinoma Cells in Mice
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives
Letters in Drug Design & Discovery Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Targeting Triglyceride Metabolism for Colorectal Cancer Prevention and Therapy
Current Drug Targets Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Antimutagenic Activity of Lutein –An Oxycarotenoid Present in the Macula and its Inhibition of Cytochrome P 450 Enzymes in vitro
Drug Metabolism Letters Review the Application of Chromatography in the Analysis of Nitric Oxide-derived Nitrite and Nitrate Ions in Biological Fluids
Current Analytical Chemistry Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Current Drug Metabolism Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations
Current Topics in Medicinal Chemistry Synthesis of Monosulfated Lewis a Trisaccharide Library Through Sulfation of a Partial Protected Trisaccharide
Letters in Organic Chemistry <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
Current Drug Metabolism